Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. reported its third-quarter financial results for 2026, showing a significant increase in net loss to $73.6 million, up from $42.2 million in the same period of 2025. This widening loss was driven by higher operating expenses, particularly in research and development, which rose to $67.6 million from $39.9 million year-over-year. The company's balance sheet reflects a decrease in cash and marketable securities, and a reduction in total assets and stockholders' equity, while total liabilities increased.

Olema Pharmaceuticals, Inc. has appointed Jason O’Byrne as its new Chief Financial Officer, effective August 11, 2026. Mr. O'Byrne brings over two decades of finance and global operations leadership from biopharmaceutical companies, including Vir Biotechnology and Caribou Biosciences. His compensation package includes an annual base salary of $545,000, a target annual bonus of 45%, a sign-on bonus totaling $350,000, and an option to purchase 650,000 shares of common stock.

Olema Pharmaceuticals reported a net loss of $(63.2) million for Q2 2026, an increase from $(43.8) million in Q2 2025. Research and development expenses rose significantly to $57.8 million, up 31.6% year-over-year. For the first six months of 2026, the net loss was $(116.3) million, with R&D expenses at $107.0 million. The company raised $41.9 million through an at-the-market offering during the first half of 2026 and believes its current liquidity is sufficient for at least the next 12 months.

Olema Pharmaceuticals reported its Q2 2026 financial and operating results, highlighting significant progress in its clinical pipeline. The company completed enrollment in its pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data anticipated in Q1 2027. Additionally, Olema presented initial Phase 1 clinical data for OP-3136 and announced a collaboration with Bayer to evaluate OP-3136 in metastatic castration-resistant prostate cancer. For the second quarter, Olema reported a net loss of $63.2 million and maintained a strong cash position of $461.1 million.

Olema Pharmaceuticals granted stock options for an aggregate of 215,800 shares of common stock to eight new employees, effective July 1, 2026. These options were issued under the Company's 2022 Inducement Plan, with an exercise price of $12.08 per share. The awards vest over four years, with a 10-year term, as an inducement for their employment.

Olema Pharmaceuticals granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective June 1, 2026. These awards were approved by the Compensation Committee and granted under the Company's 2022 Inducement Plan as an inducement for employment. The stock options vest over four years and have an exercise price of $12.71 per share, equal to the last reported sale price on June 1, 2026.

Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer AG to evaluate OP-3136, Olema's investigational KAT6 inhibitor, in combination with Bayer's NUBEQA (darolutamide). The Phase 1b/2 study will assess the safety, tolerability, and preliminary anti-tumor activity in approximately 36 patients with metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in H2 2026. Under the agreement, Bayer will supply darolutamide, Olema will lead the study, and both companies will jointly own clinical data and inventions, while Olema retains full global commercial rights to OP-3136.

Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a potent KAT6 inhibitor, demonstrating acceptable tolerability and promising anti-tumor activity as a monotherapy across multiple advanced solid tumor types. The study observed tumor shrinkage in over two-thirds of evaluable patients, including 3 partial responses (2 confirmed), with no dose-limiting toxicities or discontinuations due to adverse events. These results, supported by on-target engagement and predictable pharmacokinetics, reinforce confidence in OP-3136's potential and support ongoing Phase 1 evaluation, including combination studies. Olema will present these data and a Phase 3 trial-in-progress poster at the upcoming ASCO Annual Meeting.

Olema Pharmaceuticals, Inc. (Olema Oncology) announced its participation in three upcoming investor conferences in May and June 2026. The company will engage in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts and recordings of these presentations will be accessible on Olema's investor relations website.

Olema Pharmaceuticals reported a widened net loss of $53.1 million for the first quarter of 2026, compared to $30.4 million in the same period last year, primarily due to increased research and development expenses. The company's total operating expenses rose to $58.0 million. Despite the loss, Olema maintained a strong liquidity position with $505.3 million in cash, cash equivalents, and marketable securities, and raised $41.9 million through an at-the-market offering.